pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
ABBVIE · news · pharmadog
← back to ABBVIE
News mentioning ABBVIE
74
stories
23d
Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trial
fiercebiotech
24d
As pharma descends on China for deals, BIOSECURE Act raises intellectual property risk
biospace
24d
Sarepta names former AbbVie R&D exec Michael Severino as next CEO
biospace
24d
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
biopharma dive
25d
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
27d
Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal
endpoints
27d
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
biospace
29d
6 companies hiring in Cambridge now
biospace
29d
US ‘eroding’ lead in rare diseases a matter of national security: Report
biospace
29d
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
biospace
Jul 21, 26
Novartis stays 'geography-agnostic' in dealmaking amid flurry of China deals
biospace
Jul 20, 26
Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
biospace
Jul 20, 26
J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B deal
endpoints
Jul 18, 26
‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
fiercebiotech
Jul 17, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
Jul 16, 26
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
biopharma dive
Jul 16, 26
‘Substantially better than before’: Why India has golden opportunity to build on innovative R&D wins
fiercebiotech
Jul 14, 26
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
biopharma dive
Jul 10, 26
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
biopharma dive
Jul 9, 26
GSK ends brain drug alliance with Alector
biopharma dive
Jul 6, 26
Apogee details path to $10.9B AbbVie deal; UK starts drug pricing pilot
endpoints
Jul 6, 26
Novartis to acquire ADC developer in a deal worth up to $1.5B
biopharma dive
Jul 1, 26
Abivax shares surge as worries subside over immune drug’s cancer risk
biopharma dive
Jun 30, 26
AbbVie and Genmab's latest win brings Epkinly closer to label expansion
endpoints
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 18, 26
cAMPfield lands $180M to build gut disease drug
biopharma dive
Jun 18, 26
Biogen adds more immune drugs in $1B buyout of secretive startup RayThera
biopharma dive
Jun 11, 26
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
biopharma dive
Jun 4, 26
STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more
stat
Jun 2, 26
AbiVax falls as safety worries cloud ‘landmark’ immune drug results
biopharma dive
← prev
page 2 of 3
next →
